Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.48 |
| ▸ | NPY1R | P25929 | 7/20 | 0.48 |
| ▸ | NPY2R | P49146 | 5/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18660499 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30120978 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30121059 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29887603 | 1.00 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30081096 | 0.99 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29779796 | 0.96 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL29794145 | 0.96 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL268800 | 0.96 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL269045 | 0.96 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RNOD1 | |
| SCHEMBL30249102 | 0.96 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220288160-A1 | FUSION PROTEINS AND USES THEREOF | SYNKLINO A/S (DK) | 2022-09-15 | — | — | US | claimed |
| US-12611440-B2 | Fusion proteins and uses thereof | SYNKLINO A/S (DK) | 2026-04-28 | — | — | US | disclosed |
| US-20240147984-A1 | COMPOSITIONS FOR EX VIVO ORGAN CARE | SYNKLINO A/S (DK) | 2024-05-09 | — | — | US | disclosed |
| US-20240000822-A1 | SAFE LENTIVIRAL VECTORS FOR TARGETED DELIVERY OF MULTIPLE THERAPEUTIC MOLECULES | AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC. | 2024-01-04 | — | — | US | disclosed |
| US-11617760-B2 | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules | AMERICAN GENE TECHNOLOGIES INTERNATIONAL INC. (US) | 2023-04-04 | — | — | US | disclosed |
| CN-109071622-B | Peptides with anticancer activity | IDP研发制药有限公司（ES） | 2023-01-13 | — | — | CN | disclosed |
| US-20220288160-A1 | FUSION PROTEINS AND USES THEREOF | SYNKLINO A/S (DK) | 2022-09-15 | — | — | US | disclosed |
| EP-4039698-A1 | PEPTIDES WITH ANTI-CANCER ACTIVITY | IDP Discovery Pharma, S.L. (ES) | 2022-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611440-B2 | Fusion proteins and uses thereof | TIMCC, CX3CR1, CXCL10 | NPY4R 557/4885NPY1R 175/4885NPY2R 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.